Persistence of T-cell clones in psoriatic lesions

Archives of Dermatology

Volumn 133, Issue 6, 1997, Pages 703-708

  Chang, Jennie C C ^a   Smith, Lawrence R ^a   Froning, Karen J ^a   Kurland, Helen H ^a   Schwabe, Beverly J ^a   Blumeyer, Kirsten K ^a   Karasek, Marvin A ^b   Wilkinson, David I ^b   Farber, Eugene M ^b   Carlo, Dennis J ^a   Brostoff, Steven W ^a  

^a Orchestra Therapeutics Inc   (United States)

^b Psoriasis Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; LYMPHOCYTIC INFILTRATION; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; T LYMPHOCYTE;

EID: 0030965747     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.133.6.703     Document Type: Article

References (25)

1. Valdimarsson H, Baker BS, Jónsdottir I, Fay L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today. 1986; 7:256-259.
2. Griffiths CEM, Voorhees JJ. Immunological mechanisms involved in psoriasis. Springer Semin Immunopathol. 1992;13:441-454.
3. Demidem A, Taylor JR, Grammer SF, Streilein JW. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langherhans cells. J Invest Dermatol. 1991;97:454-460.
4. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med. 1994;180:283-296.
5. Onuma S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol. 1994;21:223-232.
6. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-447.
7. Howell MD, Diveley JP, Lundeen KA, et al. Limited T cell receptor β-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci USA. 1991; 88:10921-10925.
8. Paliard X, West SG, Lafferty JA, et al. Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991;253:325-329.
9. Wucherpfennig KW, Ota K, Endo N, et al. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science. 1990; 248:1016-1019.
10. Oksenberg JR, Panzara MA, Begovich AB, et al. Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 1993;362:68-70.
11. + T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes. Proc Natl Acad Sci U S A. 1994;91:9282-9286.
12. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol. 1994;130:216-224.
13. Farber EM, Cohen EN, Trozak DJ, Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol. 1991; 25:658-664.
14. Davis MM, Bjorkman PJ. T cell antigen receptor genes and T cell recognition. Nature. 1989;334:395-402.
15. + T-cells in psoriatic lesions preferentially use T-cell receptors Vβ3 and/or Vβ13.1 genes. Ann N Y Acad Sci. 1995;756:370-381.
16. Boitel B, Ermonval M, Panina-Bordignon P, Mariuzza RA, Lauzavecchia A, Acuto D. Preferential Vβ gene usage and lack of junctional sequence conservation among human T cell receptors specific for a tetanus toxin-derived peptide: evidence for a dominant role of a germline-encoded V-region in antigen/major histocompatibility complex recognition. J Exp Med. 1992;175: 765-777.
17. Kotzin BL, Leung DYM, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993;54:99-166.
18. Abe J, Takeda T, Watanabe Y, et al. Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol. 1993;151:4183-4188.
19. Uchiyama T, Miyoshi-Akiyama T, Kato H, Fujimaki W, Imanishi K, Van X-J. Superantigen properties of a novel nitrogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute systemic symptoms. J Immunol. 1993;151:4407-4413.
20. Lewis HM, Baker BS, Bokth S, et al. Restricted T-cell receptor Vβ gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br J Dermatol. 1993;129:514-520.
21. Nyfors A, Lemholt K. Psoriasis in children: a short reveiw and a survey of 245 cases. Br J Dermatol. 1975;92:437-442.
22. Schmitt-Egenolf M, Boehncke W-H, Christophers E, Ständer M, Sterry W. Type I and type II psoriasis show a similar usage of T-cell receptor variable regions. J Invest Dermatol. 1991;97:1053-1056.
23. Leung DYM, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol. 1993;100:225-228.
24. Menssen A, Trommler P, Vollmer S, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol. 1995;155:4078-4083.
25. Nikaein A, Phillips C, Gilbert SC, et al. Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol. 1991;96:3-9.